On Aug. 1, 2023, BD announced that the U.S. Food and Drug Administration (FDA) 510(k) had provided clearance for the BD Respiratory Viral Panel (RVP) for BD MAX System, a single molecular diagnostic combination test that identifies and distinguishes SARS-CoV-2, influenza A, influenza B, and Respiratory Syncytial Virus (RSV) in approximately two hours.